Compare Ascendis Pharma A/S (ASND) vs VanEck JP Morgan EM Local Currency Bond ETF (EMLC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.55. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | EMLC | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $26.59 |
52-Week Low | $163.32 | $24.83 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
EMLC trades at $25.55, up 0.43% on the day, with a bearish technical signal driven by moving averages. The ETF offers a trailing yield near 6.1%, supported by consistent monthly dividends, but lacks disclosed financial ratios. Recent news highlights institutional demand for emerging market bonds amid shifting Fed policy and geopolitical risks.
The outlook is mixed: high yield attracts income investors, but currency risk and capital erosion concerns persist. Short interest has surged 73%, reflecting skepticism. Key catalysts include Fed rate decisions and emerging market volatility, presenting opportunity for yield-seeking investors with high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →
